Eli Lilly FRα ADC launches Phase III clinical study
On October 9th, the global clinical trial registry website showed that Eli Lilly launched the first Phase III clinical trial of the FRα ADC drug LY4170156 (FRAmework-01). LY4170156 is an FRα ADC drug developed by Mablink Bioscience (which has been acquired by Eli Lilly), with a payload of the topoisomerase I inhibitor irinotecan and a DAR value of 8. According to the pharmaceutical database NextPharma, there are currently 27 FRα ADC drugs under development globally, of which 11 are in clinical stages. In addition to the already marketed somatuzumab, Rinatabart sesutecan (Genmab), BAT8006 (BIO-THERA), and LY4170156 are the three drugs making the fastest progress, all having initiated Phase III clinical trials
According to the Zhitong Finance APP, on October 9th, the global clinical trial registration website showed that Eli Lilly (LLY.US) has initiated the first Phase III clinical trial (FRAmework-01) for the FRα ADC drug LY4170156. LY4170156 is an FRα ADC drug developed by Mablink Bioscience (which has been acquired by Eli Lilly), with an effective payload of the topoisomerase I inhibitor irinotecan and a DAR value of 8.
According to the NextPharma database, there are currently 27 FRα ADC drugs under development globally, of which 11 are in the clinical stage. In addition to the already marketed somatuzumab, Rinatabart sesutecan (Genmab), BAT8006 (BIO-THERA), and LY4170156 are the three drugs making the fastest progress, all of which have initiated Phase III clinical trials
